이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MorphoSys 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Arkadius Pichota

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	6.4yrs

최근 관리 업데이트

Recent updates

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Apr 17

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Nov 26

CEO

Arkadius Pichota

no data

테뉴어

Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	4.4yrs	€1.10m	0.0036% € 91.4k
Arkadius Pichota	Chief Executive Officer	no data	데이터 없음	데이터 없음
Lukas Gilgen	Chief Financial Officer	no data	데이터 없음	데이터 없음
Tim Demuth	Chief Research & Development Officer	1.7yrs	데이터 없음	데이터 없음
Klaus De Wall	Head of Accounting & Tax	no data	데이터 없음	데이터 없음
Margit Urban	Head of Discovery Alliances & Technologies	no data	데이터 없음	데이터 없음
Julia Neugebauer	Head of Investor Relations	no data	데이터 없음	데이터 없음
Barbara Krebs-Pohl	Chief Business Officer	no data	데이터 없음	데이터 없음
Günter Wellnhofer	Head of Technical Operations	no data	데이터 없음	데이터 없음
Harald Watzka	Head of Alliance Management	no data	데이터 없음	데이터 없음
Yen Ching Chua	Head of Clinical Operations	no data	데이터 없음	데이터 없음
Kathrin Tissot	Head of Business Team	no data	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

경험이 풍부한 관리: MOR 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Bruce Cheson	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Gunther Adolf	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Sergio Quezada	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Raymond Sweet	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Sharon Curran	Independent Member of Supervisory Board	5yrs	€92.60k	데이터 없음
Heinrich V. Moisa	Chairman of the Supervisory Board	less than a year	데이터 없음	데이터 없음
Silke Mainka	Member of the Supervisory Board	less than a year	데이터 없음	데이터 없음
Romain Lege	Deputy Chairman of the Supervisory Board	less than a year	데이터 없음	데이터 없음

6.4yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: MOR 의 이사회는 경험(평균 재직 기간 6.4 년)으로 간주됩니다.

MorphoSys 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

MorphoSys AG Announces Board Changes

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

MorphoSys AG Announces Executive Changes

Recent updates

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

Consensus EPS estimates fall by 167%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Price target increased by 13% to €35.50

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 43%

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 17%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 16%

Morphosys AG Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Price target increased by 8.0% to €31.61

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to €25.94

Consensus EPS estimates upgraded to €6.45 loss

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 12%

Price target increased by 7.3% to €19.64

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 27% to €18.25

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Price target decreased to €24.05

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Price target decreased to €26.50

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €32.45

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

Price target decreased to €37.06

MorphoSys AG Announces Executive Changes

Consensus EPS estimates fall by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO

테뉴어

리더십 팀